Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Jan;92(1):74–82. doi: 10.1111/j.1349-7006.2001.tb01050.x

Schedule‐dependent Synergism and Antagonism between Raltitrexed (“Tomudex”) and Methotrexate in Human Colon Cancer Cell Lines in vitro

Yasuhiko Kano 1,✉, Miyuki Akutsu 1, Saburo Tsunoda 1, Kenichi Suzuki 2, Yasuo Yazawa 3, Yusuke Furukawa 4
PMCID: PMC5926578  PMID: 11173547

Abstract

The folate‐dependent enzymes are attractive targets for cancer chemotherapy. Methotrexate (MTX), which inhibits dihydrofolate reductase, has been widely used for the treatment of solid tumors and hematological cancers. Raltitrexed (“Tomudex”), which inhibits thymidylate synthase, is a novel anticancer agent active against colorectal cancer and some other solid tumors. We studied the optimal schedule of raltitrexed and MTX in combination against four human colon cancer cell lines Colo201, Colo320, LoVo, and WiDr. These cells were simultaneously exposed to raltitrexed and MTX for 24 h, or sequentially exposed to raltitrexed for 24 h followed by MTX for 24 h, or vice versa. Cell growth inhibition after 5 days was determined by using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. The effects of drug combinations at the concentrations of drug that produced 80% and 50% cell growth inhibition (Icg80 and IC50) were analyzed by the isobologram method (Steel and Peckham, 1979). Cytotoxic interactions between raltitrexed and MTX were schedule‐dependent. The simultaneous exposure to raltitrexed and MTX showed additive effects in Colo201, LoVo and WiDr cells and antagonistic effects in Colo320 cells. The sequential exposure to raltitrexed followed by MTX produced additive effects in all four cell lines. The sequential exposure to MTX followed by raltitrexed produced synergistic effects in Colo201, LoVo and WiDr cells and additive effects in Colo320 cells. These findings suggest that the sequential administration of MTX followed by raltitrexed produces more than the expected cytotoxicity and may be the optimal schedule at the cellular level. Further in vivo and clinical studies will be necessary to determine the toxicity and to test the antitumor effects of sequential administration of MTX followed by raltitrexed proposed on the basis of the in vitro synergism.

Keywords: Raltitrexed, Methotrexate, Synergism, Isobologram, Colon cancer

Full Text

The Full Text of this article is available as a PDF (162.6 KB).

References

  • 1.Chu , E. . and Allegra , C. J.Antifolates . In “Cancer Chemotherapy and Biotherapy,” 2nd Ed. , ed. Chabner B. A. and Longo D. L. . pp . 109 – 148 ( 1996. ). Lippincott‐Raven; , Philadelphia . [Google Scholar]
  • 2.Rustum , Y. M. , Harstrick , A. , Cao , S. , Vanhoefer , U. , Yin , M. B. , Wilke , H. . and Seeber , S.Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors . J. Clin. Oncol. , 15 , 389 – 400 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 3.Jackman , A. L. , Taylor , G. A. , Gibson , W. , Kimbell , R. , Brown , M. , Calvert , A. H. , Judson , I. R. . and Hughes , L. R.ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study . Cancer Res. , 51 , 5579 – 5586 ( 1991. ). [PubMed] [Google Scholar]
  • 4.Clarke , S. J. , Hanwell , J. , de Boer , M. , Planting , A. , Verweij , J. , Walker , M. , Smith , R. , Jackman , A. L. , Hughes , L. R. , Harrap , K. R. , Kennealey , G. T. . and Judson , I. R.Phase I trial of ZD1694, a new folate‐based thymidylate synthase inhibitor, in patients with solid tumors . J. Clin. Oncol. , 14 , 1495 – 1503 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 5.Bearle , P. , Judson , L , Hanwell , J. , Berry , C. , Aherne , W. , Hickish , T. , Martin , P. . and Walker , M.Metabolism, excretion and pharmacokinetics of a single dose of [14C]raltitrexed in cancer patients . Cancer Chemother. Pharmacol. , 42 , 71 – 76 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 6.Zalcberg , J. R. , Cunningham , D. , van Custem , E. , Francois , E. , Schornagel , J. , Adenis , A. , Green , M. , Iveson , A. , Azab , M. . and Seymour , I.ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colo‐rectal Study Group . J. Clin. Oncol. , 14 , 716 – 721 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 7.Smith , L , Jones , A. , Spielmann , M. , Namer , M. , Green , M. D. , Bonneterre , J. , Wander , H. E. , Hatschek , T. , Wilking , N. , Zalcberg , J. , Spiers , J. . and Seymour , L. A.Phase II study in advanced breast cancer: ZD1694 (‘Tomudex’) a novel direct and specific thymidylate synthase inhibitor . Br. J. Cancer , 74 , 479 – 481 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Blackledge , G.New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (‘Tomudex’) . Br. J. Cancer , 77 ( Suppl. 2 ), 29 – 37 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cunningham , D.Mature results from three large controlled studies with raltitrexed (‘Tomudex’) . Br. J. Cancer , 77 ( Suppl. 2 ), 15 – 21 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial . J. Clin. Oncol. , 7 , 1437 – 1446 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 11.The Advanced Colorectal Cancer Meta‐Analysis Project. Meta‐analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer . J. Clin. Oncol. , 12 , 960 – 969 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 12.Steel , G. . and Peckham , M. J.Exploitable mechanisms in combined radiotherapy‐chemotherapy: the concept of addi‐tivity . Int. J. Radial. Oncol. Biol. Phys. , 5 , 85 – 93 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 13.Kano , Y. , Sakamoto , S. , Kakahara , T. , Akutsu , M. , Inoue , Y. . and Miura , Y.In vitro effects of amsacrine in combination with other anti‐cancer agents . Leukemia Res. , 15 , 1059 – 1066 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 14.Kano , Y. , Ohnuma , T. , Okano , T. . and Holland , J. F.Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture . Cancer Res. , 48 , 351 – 356 ( 1988. ). [PubMed] [Google Scholar]
  • 15.Kano , Y. , Akutsu , M. , Tsunoda , S. , Suzuki , K. . and Adachi , K.In vitro schedule‐dependent interaction between raltitrexed and SN‐38 (the active metabolite of irinotecan) in human carcinoma cell lines . Cancer Chemother. Pharmacol. , 42 , 91 – 98 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 16.Kano , Y. , Akutsu , M. , Suzuki , K. , Yazawa , Y. . and Tsunoda , S.Schedule‐dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro . Jpn. J. Cancer Res. , 91 , 424 – 432 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kano , Y. , Akutsu , M. , Suzuki , K. , Yazawa , Y. , Tsunoda , S. . and Furukawa , Y.Schedule‐dependent interaction between raltitrexed and 5‐fluorouracil in human colon cancer cell lines in vitro . Oncol. Res. , in press . [DOI] [PubMed] [Google Scholar]
  • 18.Ackland , S. , Kuiper , C. M. , Carg , M. , Bergman , A. M. , Smid , K. . and Peters , G. J.Variable effects of the combination of tomudex (ZD1694) and cisplatin in ovarian cancer cell lines (abstract) . Ann. Oncol. , 7 , 7 ( 1996. ). [Google Scholar]
  • 19.Aschele , C. , Baldo , C. , Sobrero , A. R , Debernardis , D. , Bornmann , W. G. . and Bertino , J. R.Schedule‐dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro . Clin. Cancer Res. , 4 , 1323 – 1330 ( 1998. ). [PubMed] [Google Scholar]
  • 20.Longo , G. S. , Izzo , J. , Chang , Y. M. , Tong , W. P. , Zielinski , Z. , Gorlick , R. , Chou , T. C. . and Bertino , J. R.Pretreatment of colon carcinoma cells with Tomudex enhances 5‐fluorouracil cytotoxicity . Clin. Cancer Res. , 4 , 469 – 473 ( 1998. ). [PubMed] [Google Scholar]
  • 21.Bertino , J. R. , Sawicki , W. L. , Linquist , C. A. . and Gupta , V. S.Schedule‐dependent antitumor effects of methotrex‐ate and 5‐fluorouracil . Cancer Res. , 37 , 327 – 328 ( 1977. ). [PubMed] [Google Scholar]
  • 22.Cadman , E. , Dacis , L. . and Heimer , R.Enhanced 5‐fluorouracil nucleotide formation following methotrexate: biochemical explanation for drug synergism . Science , 205 , 1135 – 1137 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 23.Matsui , S. L , Arredondo , M. A. , Wizosek , C. . and Rustum , Y. M.DNA damage and p53 induction do not cause ZD1694‐induced cell cycle arrest in human colon carcinoma cells . Cancer Res. , 56 , 4715 – 4723 ( 1996. ). [PubMed] [Google Scholar]
  • 24.Tonkinson , J. L. , Harder , P. , Andis , S. L. , Schultz , R. M. , Gosseett , L. S. , Shih , C. . and Mendelsohn , L. G.Cell cycle effects of antifolate antimetabolites: implications for cyto‐ toxicity and cytostasis . Cancer Chemother. Pharmacol. , 39 , 521 – 531 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 25.Akutsu , M. , Kano , Y. , Tsunoda , S. , Suzuki , K. , Yazawa , Y. . and Miura , Y.Schedule‐dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro . Eur. J. Cancer , 31A , 2341 – 2346 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 26.Holmes , F. A. , Madden , T. , Newman , R. A. , Valero , V. , Theriault , R. L. , Fraschini , G. , Walters , R. S. , Booser , D. J. , Buzdar , A. U. , Willey , J. . and Hortobagyi , G. N.Sequence‐dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer . J. Clin. Oncol. , 14 , 2713 – 2721 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 27.Holmes , F. A. , Valero , V. , Walters , R. S. , Theriault , R. L. , Booser , D. J. , Gibbs , H. , Fraschini , G. , Buzdar , A. U. , Willey , J. , Frye , D. , Asmar , L. . and Hortobagyi , G. N.Paclitaxel by 24‐hour infusion with doxorubicin by 48‐hour infusion as initial therapy for metastatic breast cancer: phase I results . Ann. Oncol , 10 , 403 – 411 ( 1999. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES